Bluejay Diagnostics заключила стратегическое партнерство с Lovell для выхода на рынок федерального здравоохранения США

Bluejay Diagnostics (BJDX)announced a distribution, co-marketing and strategic partnership with Lovell Government Services to expand access to U.S. federal healthcare markets, pending FDA clearance. Under the agreement, Lovell will serve as Bluejay's exclusive distributor for federal procurement opportunities requiring or favoring Service-Disabled Veteran-Owned Small Business (SDVOSB) set-aside and preferred status, including opportunities within the U.S. Department of Veterans Affairs (VA), Department of Defense (DoD), Military Health Systems (MHS) and Indian Health Service (IHS). Lovell will also have non-exclusive rights to participate in open-market federal, state and local government procurement opportunities, providing Bluejay with additional potential channels to reach government healthcare customers. The partnership aims to build federal market access and procurement infrastructure ahead of potential commercialization, subject to FDA clearance. The Veterans Health Administration (VHA), the largest integrated healthcare system in the U.S., encompasses approximately 170 major medical centers and 1,193 outpatient clinics, with a proposed fiscal 2026 budget of approximately $165.1 billion. The broader federal healthcare market also includes approximately 45 U.S. military hospitals and 572 military medical clinics within the DoD healthcare system. The Defense Health Agency (DHA) has a proposed fiscal 2026 budget of approximately $64 billion. The Indian Health Service (IHS), with a proposed fiscal 2026 budget of approximately $8.1 billion, serves approximately 2.8 million American Indians and Alaska Natives through approximately 170 IHS and tribally managed service units. Lovell will leverage its SDVOSB status, federal contracting capabilities and industry relationships to support market development, facilitate introductions and pursue federal procurement opportunities for Bluejay. The companies may also collaborate on educational initiatives, conferences, customer engagement and other federal market-development activities. Lovell's federal procurement infrastructure includes access to contract vehicles such as the VA Federal Supply Schedule (FSS), GSA Advantage, GSA Multiple Award Schedule (MAS), Defense Logistics Agency (DLA) DAPA and Electronic Catalog (ECAT). ECAT is a preferred DoD procurement vehicle for medical supplies and devices and is also utilized by the VA and IHS. Bluejay's Symphony System is an investigational rapid diagnostic platform designed for sepsis triage and monitoring of disease progression. Its first product candidate, an IL-6 Test for sepsis, is designed to provide results in approximately 20 minutes from sample-to-result to support earlier and more informed triage and treatment decisions. The SYMON Clinical Study Program includes SYMON-I, SYMON-II and SYMON-III. SYMON-I is a pilot study evaluating IL-6 levels associated with outcomes including 28- day all-cause mortality and in-hospital mortality, while SYMON-II is the pivotal study intended to validate SYMON-I findings and support a planned 510(k) submission to the FDA. SYMON-III is a pilot study evaluating IL-6 levels in patients presenting with increasing severity of infection in the emergency department and their risk of developing sepsis. Bluejay noted that the Symphony System does not yet have FDA regulatory clearance and remains limited by U.S. law to investigational use. The company plans to advance regulatory, clinical, manufacturing and commercial readiness in parallel as it prepares for potential future commercialization. BJDX closed Friday's trade at $0.83, down 1.94%. In the premarket trading, the stock is trading up 19.37% at $0.99. For comments and feedback contact: [email protected] Business News September 11, 2026 16:26 ET Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.